$2.385
+0.078 (+3.25%)收盤時
IKT 資訊
IKT 事件
Inhibikase Advances IKT-001 Clinical Study and Receives FDA Orphan Drug Designation
"During our second quarter and in recent weeks we continued to advance our Phase 3 IMPROVE-PAH study with 26 country regulatory approvals together with the recent initiation of 43 clinical sites across a range of countries," said Mark Iwicki, Chief Executive Officer of Inhibikase. "Also, during the quarter, favorable results of pre-clinical and Phase 1 studies of IKT-001 were presented at the American Thoracic Society International Conference, with data demonstrating improvements in pulmonary vascular and hemodynamic markers of PAH and lower potential for GI toxicity compared to imatinib mesylate. Together with the recent grant of Orphan Drug Designation from the U.S. FDA and the $50 million proceeds from the sale of shares to RA Capital, Inhibikase is well-positioned to advance IKT-001 toward its potential as the first once-daily oral anti-proliferative offering significant potential benefits to the PAH patient population."
Inhibikase Therapeutics Receives Orphan Drug Designation for IKT-001
Inhibikase Therapeutics announced that the FDA has granted Orphan Drug Designation to its lead product candidate IKT-001, a prodrug of imatinib mesylate, for the treatment of PAH.
Inhibikase Therapeutics Enrolls First Patient in Pivotal Phase 3 IMPROVE-PAH Study
Inhibikase Therapeutics announced that the first patient has been enrolled in the company's pivotal Phase 3 study IMPROVE-PAH study.
Stocks Fluctuate Near All-Time Highs, S&P 500 Slightly Declines
The post-Christmas session saw stocks fluctuate near all-time highs and the indexes close little changed following a day of thin trading. While the S&P 500 saw a very small daily drop, it still closed with its best week in a month.Get caught up quickly on the top news and calls moving stocks with this recap from The Fly.1. STOCK NEWS:Nvidialicensingand hiring top executives, including its CEO, in deal reported to be worth $20BTargetfacing pressure from activist investor Toms Capital,Biohavenannounced on Christmas Eve that its Phase 2 proof-of-concept study evaluating BHV-7000 for the treatment of major depressive disorderWALL STREET CALLS:Inhibikase Therapeuticswith a Buy at H.C. WainwrightCarter Bankshareswith a Buy at Freedom CapitalMDU Resourceswith a Hold at Freedom CapitalWalmartwith an Outperform at CICC3. AROUND THE WEB:Following the Trump administration's approval of a weapons sale to Taiwan, the Chinese government imposed sanctions on 20 U.S. defense companies and 10 of their executives, with targets including Northrop Grumman (NOC), Boeing'sdefense unit,A federal judge denied Masimo'srequest to block Apple Watchimports as part of its lawsuit over an earlier import ban related to patents covering blood-oxygen sensors,Hyattis developing collaborations with Chinese state-owned companies for joint-venture brands amid a slowdown in the region and an effort to expand outside Greater China to double properties in Asia,JPMorgan Chasein recent months has frozen accounts used by at least two fast-growing stablecoin startups, highlighting the risk that Cryptocurrency transactions pose for banks, which are required to know the people they do business with and the source of their cash,4. MOVERS:Coupanggained afterthe company identified the former employee responsible for the recent data leakNikerose after UBS said its recentfor the companyArcadia Biosciencesfell afterand resumption of its process of evaluating strategic alternativesMakers of wound-care products, including Organogenesis, declined after regional Medicare contractorsand tissue repair productsINDEXES:The Dow fell 0.04%, or 20.19, to 48,710.97, the Nasdaq slipped 0.09%, or 20.21, to 23,593.10, and the S&P 500 declined 0.03%, or 2.11, to 6,929.94.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。